Jpmorgan Chase & CO Biomea Fusion, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BMEA
# of Institutions
120Shares Held
17.9MCall Options Held
978KPut Options Held
286K-
Cormorant Asset Management, LP Boston, MA3.57MShares$31.6 Million1.24% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$20.7 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$18.6 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.39MShares$12.3 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.1MShares$9.72 Million0.01% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $259M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...